Structure Therapeutics(GPCR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS ...